



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND POWER OF ATTORNEY BY ASSIGNEE AND
ELECTION OF ASSIGNEE TO CONDUCT PROSECUTION TO EXCLUSION
OF INVENTORS

Under 37 CFR §3.73(b), DrugAbuse Sciences SAS, certifies that it is the assignee of 100% of the right, title and interest in the patent applications identified on the attached Appendix (Table 1) by virtue of assignments from the inventors of the patent applications. The assignment for provisional patent application serial no. 60/420,582 was recorded in the Patent and Trademark Office at the Reel and Frame numbers provided in the attached Appendix. A copy of the executed assignment for serial no. 10/533,051 is attached herewith.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the listed patents and patent applications and appoints the practitioners associated with:

PTO Customer No.:
26181

as its attorneys to prosecute the patent applications listed on the attached Appendix (Table 1) and to transact all business in the United States Patent and Trademark Office connected therewith with full powers of substitution and revocation, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 CFR §3.71 *et seq.* of the Patent and Trademark Office Rules of Practice.

All correspondence regarding the listed applications should be sent to:

PTO Customer Number:
26181

Direct all telephone calls to Richard G. A. Bone, Reg. No. 56,637, at telephone number (650) 839-5070.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the applications or any patents issued thereon.


Signature:  _____
Typed name: Ross Maclean, Ph.D.
Title: CEO
Assignee: DrugAbuse Sciences SAS
Date: 29 MARCH 2006

TABLE 1

DrugAbuse Sciences SAS

Attorney Docket No.	Application Serial No.	Patent No.	Recordation Date Reel/Frame
19604-005P01	60/420,582	n/a	11/18/2002 013494/0983
19604-005US1	10/533,051	n/a	(copy of executed assignment attached herewith)

COPY

Attorney Docket No.: 19604-005US1



OFFICIAL COMMUNICATION FACSIMILE

TO THE ATTENTION OF:

MAIL STOP ASSIGNMENT

MAIL STOP ASSIGNMENT FAX NO: 571/273-0140

Number of pages including this page 3 pages

Applicant : Jacques Kusmierck

Art Unit : Unknown

Serial No. : 10/533,051

Examiner : Unknown

Filed : April 26, 2005

Title : Treatment of Cognitive Impairment Using a Selective Dopamine D1 Receptor Agonist

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attached to this facsimile communication cover sheet is a Recordation Form Cover Sheet and Assignment, faxed this 7th day of April, 2006, to Mail Stop Assignment Recordation Services, U.S. Patent and Trademark Office.

Date: April 7, 2006

Respectfully submitted,

Richard G. A. Bone

Reg. No. 56,637



PTO Customer No. 26181
Fish & Richardson P.C.
500 Arguello Street, Suite 500
Redwood City, California 94063
Telephone: (650) 839-5070
Fax: (650) 839-5071

50329688.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (650) 839-5070 to arrange for its return. Thank you.



RECORDATION FORM COVER SHEET PATENTS ONLY


Commissioner for Patents: Please record the attached original document(s) or copy(ies).	
1. Name of conveying party(ies): Jacques Kusmierek Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): DrugAbuse Sciences SAS 116 rue la Boétie 75008 Paris France Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: Execution Date: 03/27/2006	
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: A. Patent Application No(s): 10/533,051 B: Patent No(s): Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name/address of party to whom correspondence concerning document should be mailed: PTO CUSTOMER NO. 26181	6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$40 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.
DO NOT USE THIS SPACE	
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>	
Richard G. A. Bone Reg. No. 56,637 Name of Person Signing	 Signature  Date
Total number of pages including coversheet, attachments and document: 3 pages	

50329686.doc

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

April 7, 2006
Date of Transmission


Signature

Emma Durrell
Typed Name of Person Signing Certificate

ASSIGNMENT

For valuable consideration, I, Jacques Kusmierek, of 116 rue la Boétie, 75008 Paris France; hereby assign to DRUGABUSE SCIENCES SAS, a corporation of France, having a place of business at 116 rue la Boétie, 75008 Paris, France, and its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent signed by us, entitled TREATMENT OF COGNITIVE IMPAIRMENT USING A SELECTIVE DOPAMINE D1 RECEPTOR AGONIST, filed April 26, 2005, and assigned U.S. Serial Number 10/533,051, this assignment including said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

DATE: MARCH 27th 2006/s/ MichelJACQUES KUSMIEREK

Witnessed By:

Date

Printed Name

50330134.doc